^
    over1year
    STAR CNS: GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma (clinicaltrials.gov)
    P1b/2, N=12, Terminated, GB005, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | N=158 --> 12 | Trial completion date: Oct 2024 --> May 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2024 --> May 2023; Sponsor decision
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    GB5121
    2years
    GB5121, a Brain-Penetrant, Irreversible BTK Inhibitor, Demonstrates Potent Anti-Tumor Activity in a Novel Mouse Model of Intracranial Lymphoma (ASH 2022)
    GB5121 was designed to be a brain-penetrant BTKi; a PET imaging study confirms the results of previously conducted NHP PK studies demonstrating CNS penetration of GB5121. In a novel model of intracranial lymphoma, treatment with GB5121 resulted in better anti-tumor activity compared to ibrutinib, likely resulting from higher brain penetration and TO. This higher brain penetration and TO exhibited by GB5121 may result in more durable responses in malignancies with CNS involvement and supports the investigation of GB5121 in clinical trials for CNS lymphomas.
    Preclinical
    |
    CD20 (Membrane Spanning 4-Domains A1) • IL10 (Interleukin 10)
    |
    CD20 positive
    |
    Imbruvica (ibrutinib) • GB5121